{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000140","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.122815+00:00","generated_at":"2026-05-29T05:12:40.758338+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arvinas/Pfizer report vepdegestrant+abemaciclib Phase 1b: 62.5% CBR, 26.7% ORR in post-CDK4/6 breast cancer","bullets":["62.5% clinical benefit rate (10/16) and 26.7% ORR (4/15) in ER+/HER2- advanced breast cancer patients all previously treated with CDK4/6 inhibitor.","No significant drug-drug interaction between vepdegestrant (200mg QD) and abemaciclib (150mg BID); no grade 4/5 TEAEs.","Recommended Phase 2 dose confirmed: vepdegestrant 200mg QD + abemaciclib 150mg BID; Phase 2 portion ongoing.","Data cut-off Aug 30, 2024; presented Dec 12, 2024 at SABCS; 5 of 16 patients remain on treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000140","json":"https://secwatch.observer/filing/0001655759-24-000140.json","markdown":"https://secwatch.observer/filing/0001655759-24-000140.md","text":"https://secwatch.observer/filing/0001655759-24-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/0001655759-24-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/arvn-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:12:40.758338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}